Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
Saved in:
| Title: | Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. |
|---|---|
| Authors: | King, Brett1 (AUTHOR), McMichael, Amy2 (AUTHOR), Sinclair, Rodney3 (AUTHOR), Vañó-Galvan, Sergio4 (AUTHOR), Wolk, Robert5 (AUTHOR), Woodworth, Deborah6 (AUTHOR), Soma, Koshika5 (AUTHOR), Robbana, Feriel7 (AUTHOR) Feriel.Robbana@pfizer.com, Lejeune, Alexandre8 (AUTHOR), Napatalung, Lynne9,10 (AUTHOR), Law, Ernest9 (AUTHOR), Wajsbrot, Dalia5 (AUTHOR), Wang, Cunshan5 (AUTHOR), Roychoudhury, Satrajit9 (AUTHOR) |
| Source: | Dermatology & Therapy. Dec2025, Vol. 15 Issue 12, p3793-3803. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938210 |
|---|---|
| DOI: | 10.1007/s13555-025-01543-7 |
